Bookmarks
Real-World Effectiveness of Denosumab in Prevention of Fracture among Postmenopausal Osteoporotic Women with FREEDOM Baseline Characteristics
Safe People
Organisation name
University of Oxford
Organisation sector
Academic Institute
Applicant name(s)
Daniel Prieto-Alhambra - Chief Investigator - University of OxfordVictoria Y Strauss - Corresponding Applicant - University of OxfordAnnika Jodicke - Collaborator - University of OxfordAntonella Delmestri - Collaborator - University of OxfordEng Hooi Tan - Collaborator - University of OxfordJoe Maskell - Collaborator - Amgen Ltd
Safe Projects
Project ID
CPRD30
Lay summary
BACKGROUND: A clinical trial, entitled 'FREEDOM', showed that denosumab, a new anti-osteoporosis drug, was efficient in reducing the risk of having a fracture in postmenopausal women suffering from osteoporosis.
Technical summary
OBJECTIVES:
Latest approval date
20/05/2021
Safe Data
Dataset(s) name
HES Admitted Patient Care
ONS Death Registration Data
Patient Level Index of Multiple Deprivation
Safe Setting
Access type
Release